NOVO NORDISK A/S-B (NOV.DE) Stock Price, Forecast & Analysis
Europe • Frankfurt Stock Exchange • FRA:NOV • DK0062498333
NOV.DE Key Statistics, Chart & Performance
The current stock price of NOV.DE is 41.925 EUR. In the past month the price decreased by -18.59%. In the past year, price decreased by -44.12%.
NOV.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NOV.DE. When comparing the yearly performance of all stocks, NOV.DE is a bad performer in the overall market: 90.73% of all stocks are doing better.
NOV.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE. While NOV.DE belongs to the best of the industry regarding profitability, there are concerns on its financial health.
NOV.DE Financial Highlights
Over the last trailing twelve months NOV.DE reported a non-GAAP Earnings per Share(EPS) of 3.12. The EPS increased by 3.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 33.14% | ||
| ROA | 18.87% | ||
| ROE | 52.79% | ||
| Debt/Equity | 0.61 |
NOV.DE Forecast & Estimates
32 analysts have analysed NOV.DE and the average price target is 54.04 EUR. This implies a price increase of 28.91% is expected in the next year compared to the current price of 41.925.
For the next year, analysts expect an EPS growth of -2.28% and a revenue growth 0.24% for NOV.DE
NOV.DE Ownership
NOV.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SNW | SANOFI | 9.74 | 193.996B | ||
| SAN | SANOFI | 9.72 | 193.923B | ||
| 1SAN | SANOFI | 9.5 | 193.923B | ||
| MRK | MERCK KGAA | 14.61 | 53.608B | ||
| 1MRK | MERCK KGAA | 14.2 | 53.065B | ||
| UCB | UCB SA | 25.77 | 51.798B | ||
| UNC | UCB SA | 25.81 | 51.37B | ||
| 1BAYN | BAYER AG-REG | 9.48 | 45.678B | ||
| BAYN | BAYER AG-REG | 9.45 | 45.466B | ||
| IPN | IPSEN | 12.25 | 11.557B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About NOV.DE
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Info
NOVO NORDISK A/S-B
Novo Alle 1
Bagsvaerd DK
Employees: 78554
Phone: 4544448888
NOVO NORDISK A/S-B / NOV.DE FAQ
What does NOV do?
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Can you provide the latest stock price for NOVO NORDISK A/S-B?
The current stock price of NOV.DE is 41.925 EUR. The price increased by 1.34% in the last trading session.
Does NOV stock pay dividends?
NOVO NORDISK A/S-B (NOV.DE) has a dividend yield of 4.17%. The yearly dividend amount is currently 1.56.
How is the ChartMill rating for NOVO NORDISK A/S-B?
NOV.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Would investing in NOVO NORDISK A/S-B be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NOV.DE.
What is the ownership structure of NOVO NORDISK A/S-B (NOV.DE)?
You can find the ownership structure of NOVO NORDISK A/S-B (NOV.DE) on the Ownership tab.